Clinical Trials in Moers, North Rhine-Westphalia
3 recruiting
Showing 1–3 of 3 trials
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled217 locationsNCT06170788
Recruiting
Observational Study Protocol: LIVER-R
Hepatobiliary Cancers
AstraZeneca4,490 enrolled138 locationsNCT06252753
Recruiting
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
Metastatic Colorectal Carcinoma
Pierre Fabre Pharma GmbH500 enrolled70 locationsNCT04673955